Gliosarcoma: all 248 studies

Page 2 of 3. Open to participants first (15), then studies with results posted, then the rest; newest registration first within each.

• Pazopanib in Treating Patients With Recurrent GlioblastomaCompletedNCT00459381Phase 2Results posted
• Erlotinib and Sorafenib in Treating Patients With Progressive or Recurrent Glioblastoma MultiformeCompletedNCT00445588Phase 2Results posted
• Zactima With Temodar During Radiation Treatment for Newly Diagnosed Stage IV Brain TumorsCompletedNCT00441142Phase 1/2Results posted
• Bevacizumab and Irinotecan or Temozolomide in Treating Patients With Recurrent or Refractory Glioblastoma Multiforme or GliosarcomaCompletedNCT00433381Phase 2Results posted
• Dasatinib in Treating Patients With Recurrent Glioblastoma Multiforme or GliosarcomaCompletedNCT00423735Phase 2Results posted
• Phase 1/2 Study of Enzastaurin in Newly Diagnosed Glioblastoma Multiforme (GBM) and Gliosarcoma (GS) PatientsCompletedNCT00402116Phase 1/2Results posted
• Erlotinib in Treating Patients With Recurrent Glioblastoma Multiforme or GliosarcomaTerminatedNCT00387894Phase 2Results posted
• Tandutinib in Treating Patients With Recurrent or Progressive GlioblastomaCompletedNCT00379080Phase 1/2Results posted
• VEGF Trap in Treating Patients With Recurrent Malignant Gliomas That Did Not Respond to TemozolomideCompletedNCT00369590Phase 2Results posted
• Imatinib Mesylate and Hydroxyurea in Treating Patients With Recurrent or Progressive MeningiomaCompletedNCT00354913Phase 2Results posted
• Sorafenib Combined With Erlotinib, Tipifarnib, or Temsirolimus in Treating Patients With Recurrent Glioblastoma Multiforme or GliosarcomaCompletedNCT00335764Phase 1/2Results posted
• Sorafenib Tosylate and Temsirolimus in Treating Patients With Recurrent GlioblastomaCompletedNCT00329719Phase 1/2Results posted
• Motexafin Gadolinium, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme or GliosarcomaCompletedNCT00305864Phase 1/2Results posted
• Radiation Therapy (RT) and Temozolomide (TMZ) in Treating Patients With Newly Diagnosed Glioblastoma or GliosarcomaCompletedNCT00304031Phase 3Results posted
• Vorinostat in Treating Patients With Progressive or Recurrent Glioblastoma MultiformeCompletedNCT00238303Phase 2Results posted
• Safety and Efficacy Study of Tarceva, Temodar, and Radiation Therapy in Patients With Newly Diagnosed Brain TumorsCompletedNCT00187486Phase 2Results posted
• Cilengitide in Treating Patients Who Are Undergoing Surgery for Recurrent or Progressive Glioblastoma MultiformeTerminatedNCT00112866Phase 2Results posted
• Erlotinib and Temsirolimus in Treating Patients With Recurrent Malignant GliomaCompletedNCT00112736Phase 1/2Results posted
• Radiation Therapy, Temozolomide, and Lomustine in Treating Young Patients With Newly Diagnosed GliomasCompletedNCT00100802Phase 2Results posted
• Lapatinib in Treating Young Patients With Recurrent or Refractory Central Nervous System TumorsCompletedNCT00095940Phase 1/2Results posted
• FR901228 in Treating Patients With Recurrent High-Grade GliomasCompletedNCT00085540Phase 1/2Results posted
• Cilengitide, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma MultiformeCompletedNCT00085254Phase 1/2Results posted
• A Phase I/II Trial of BMS-247550 for Treatment of Patients With Recurrent High-Grade GliomasCompletedNCT00045708Phase 1/2Results posted
• Erlotinib in Treating Patients With Recurrent Malignant Glioma or Recurrent or Progressive MeningiomaCompletedNCT00045110Phase 1/2Results posted
• Gefitinib and Radiation Therapy in Treating Children With Newly Diagnosed GliomasCompletedNCT00042991Phase 1/2Results posted
• Carboxyamidotriazole + RT in Treating Patients Newly Diagnosed Supratentorial GBMCompletedNCT00004146Phase 2Results posted
• Phase I Pilot Study to Evaluate the Anti-glioblastoma Effect of S-Gboxin in Standard Treatment of Glioblastoma/Diffuse Midline Glioma and Response to Treatment (Regardless of Mutation Status)SuspendedNCT06806228Phase 1
• A Phase IB 2 Dose Trial of IRS-1 HSV C134 (IND 17296) Administered Intratumorally in Patients With Recurrent Malignant GliomaActive, not recruitingNCT06614855Phase 1
• Phase 2a Immune Modulation With Ultrasound for Newly Diagnosed GlioblastomaActive, not recruitingNCT05864534Phase 2
• Efineptakin Alfa and Pembrolizumab for the Treatment of Recurrent GlioblastomaActive, not recruitingNCT05465954Phase 2
• Testing the Addition of the Chemotherapy Drug Lomustine (Gleostine) to the Usual Treatment (Temozolomide and Radiation Therapy) for Newly Diagnosed MGMT Methylated GlioblastomaActive, not recruitingNCT05095376Phase 3
• Natural Progesterone for the Treatment of Recurrent GlioblastomaTerminatedNCT05091866Early Phase 1
• Atezolizumab and Cabozantinib for the Treatment of Recurrent GlioblastomaActive, not recruitingNCT05039281Phase 1/2
• Inducing a Hypothyroxinemic State in Patients With Recurrent Glioblastoma or GliosarcomaWithdrawnNCT05017610Early Phase 1
• ONC201 and Radiation Therapy Before Surgery for the Treatment of Recurrent GlioblastomaWithdrawnNCT04854044Phase 1
• Association of Peripheral Blood Immunologic Response to Therapeutic Response to Adjuvant Treatment With Immune Checkpoint Inhibition (ICI) in Patients With Newly Diagnosed Glioblastoma or GliosarcomaCompletedNCT04817254Phase 2
• Evaluation of Maximum Tolerated Dose, Safety and Efficiency of MSC11FCD Therapy to Recurrent Glioblastoma PatientsCompletedNCT04657315Phase 1/2
• Phase I Trial of DNA-PK Inhibitor (PEPOSERTIB ) in Combination With Radiation and Adjuvant Temozolomide in Newly Diagnosed MGMT Unmethylated and Recurrent GlioblastomaActive, not recruitingNCT04555577Phase 1
• Ultrasound-based Blood-brain Barrier Opening and Albumin-bound Paclitaxel and Carboplatin for Recurrent GlioblastomaActive, not recruitingNCT04528680Phase 1/2
• Partial Brain RT, Temozolomide, Chloroquine, and TTF Therapy for the Treatment of Newly Diagnosed GlioblastomaTerminatedNCT04397679Phase 1
• Phase I Study of Marizomib + Panobinostat for Children With DIPGTerminatedNCT04341311Phase 1
• Evaluate the Safety and Effectiveness of Intranasal Administration of Temozolomide in Patients With GlioblastomaCompletedNCT04091503Phase 1
• Ex Vivo Drug Sensitivity Testing and Mutation ProfilingCompletedNCT03860376
• Pilot Study Using Amide Proton Transfer Magnetic Resonance Imaging Distinguishing GliomaTerminatedNCT03843814Not applicable
• Dose Escalation Study of CLR 131 in Pediatric Relapsed/Refractory Malignant Tumors Including Neuroblastoma and SarcomasActive, not recruitingNCT03478462Phase 1
• Tinostamustine With or Without Radiation Therapy in Treating Patients With Newly Diagnosed MGMT-Unmethylated GlioblastomaCompletedNCT03452930Phase 1
• Multi-site Validation and Application of a Consensus DSC-MRI ProtocolStatus unknownNCT03401866Not applicable
• Vaccine Therapy in Treating Patients With Recurrent GlioblastomaCompletedNCT03360708Early Phase 1
• Intracerebral EGFR-vIII CAR-T Cells for Recurrent GBMTerminatedNCT03283631Phase 1
• Clinical Trial of the Use of the Nasal Spray of Patients With Recurrence of GlioblastomaWithdrawnNCT03275558Phase 1
• DSC-MRI in Measuring rCBV for Early Response to Bevacizumab in Patients With Recurrent GlioblastomaActive, not recruitingNCT03115333Not applicable
• Testing the Ability of AMG 232 (KRT 232) to Get Into the Tumor in Patients With Brain CancerTerminatedNCT03107780Phase 1
• BPM31510 in Treating Patients With Recurrent High-Grade Glioma Previously Treated With BevacizumabCompletedNCT03020602Phase 1
• Autologous Dendritic Cells Pulsed With Tumor Lysate Antigen Vaccine and Nivolumab in Treating Patients With Recurrent GlioblastomaWithdrawnNCT03014804Phase 2
• Gadobutrol Versus Gadopentetate Dimeglumine or Gadobenate Dimeglumine Before DCE-MRI in Diagnosing Patients With Multiple Sclerosis, Grade II-IV Glioma, or Brain MetastasesTerminatedNCT02967380Not applicable
• Combination Adenovirus + Pembrolizumab to Trigger Immune Virus EffectsCompletedNCT02798406Phase 2
• Dose Escalation Trial of Re-irradiation in Good Prognosis Recurrent GlioblastomaCompletedNCT02709226Phase 1
• Anti-LAG-3 Alone & in Combination w/ Nivolumab Treating Patients w/ Recurrent GBM (Anti-CD137 Arm Closed 10/16/18)CompletedNCT02658981Phase 1
• Phase II Sorafenib With Radiation and Temozolomide in Newly Diagnosed Glioblastoma or GliosarcomaWithdrawnNCT02599090Phase 2
• EGFRBi-Armed Autologous T Cells in Treating Patients With Recurrent or Refractory GlioblastomaWithdrawnNCT02521090Phase 1/2
• Study of the IDO Pathway Inhibitor, Indoximod, and Temozolomide for Pediatric Patients With Progressive Primary Malignant Brain TumorsCompletedNCT02502708Phase 1
• Evaluation Of The Treatment Effectiveness Of Glioblastoma / Gliosarcoma Through The Suppression Of The PI3K/Akt Pathway In Compared With MK-3475Status unknownNCT02430363Phase 1/2
• INC280 Combined With Bevacizumab in Patients With Glioblastoma MultiformeCompletedNCT02386826Phase 1
• Dimethyl Fumarate, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma MultiformeCompletedNCT02337426Phase 1
• Ipilimumab and/or Nivolumab in Combination With Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma or GliosarcomaCompletedNCT02311920Phase 1
• Tipifarnib, Radiation Therapy, and Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma MultiformeCompletedNCT02227901Phase 1
• DNX-2401 With Interferon Gamma (IFN-γ) for Recurrent Glioblastoma or Gliosarcoma Brain TumorsCompletedNCT02197169Phase 1
• Efficacy of 68Ga-DOTATOC Positron Emission Tomography (PET) CT in Children and Young Adults With Brain TumorsWithdrawnNCT02194452Not applicable
• Sapanisertib Before and After Surgery in Treating Patients With Recurrent GlioblastomaTerminatedNCT02133183Phase 1
• Lapatinib Ditosylate Before Surgery in Treating Patients With Recurrent High-Grade GliomaCompletedNCT02101905Phase 1
• Genetically Modified Stem Cells and Irinotecan Hydrochloride in Treating Patients With Recurrent High-Grade GliomasWithdrawnNCT02055196Phase 1
• Oncolytic HSV-1716 in Treating Younger Patients With Refractory or Recurrent High Grade Glioma That Can Be Removed By SurgeryTerminatedNCT02031965Phase 1
• 3T MRI Biomarkers of Glioma Treatment ResponseTerminatedNCT01996527Early Phase 1
• p28 in Treating Younger Patients With Recurrent or Progressive Central Nervous System TumorsCompletedNCT01975116Phase 1
• Vaccine Therapy and Temozolomide in Treating Patients With Newly Diagnosed GlioblastomaCompletedNCT01957956Early Phase 1
• ERC1671/GM-CSF/Cyclophosphamide for the Treatment of Glioblastoma MultiformeActive, not recruitingNCT01903330Phase 2
• A Phase I Study of Mebendazole for the Treatment of Pediatric GliomasActive, not recruitingNCT01837862Phase 1/2
• A Study of Rindopepimut/GM-CSF in Patients With Relapsed EGFRvIII-Positive GlioblastomaCompletedNCT01498328Phase 2
• Phase III Study of Rindopepimut/GM-CSF in Patients With Newly Diagnosed GlioblastomaCompletedNCT01480479Phase 3
• Temozolomide, Memantine Hydrochloride, Mefloquine, and Metformin Hydrochloride in Treating Patients With Glioblastoma Multiforme After Radiation TherapyTerminatedNCT01430351Phase 1
• High-Dose Vorinostat and Fractionated Stereotactic Body Radiation Therapy in Treating Patients With Recurrent GliomaTerminatedNCT01378481Phase 1
• Plerixafor (AMD3100) and Bevacizumab for Recurrent High-Grade GliomaTerminatedNCT01339039Phase 1
• RO4929097 in Treating Patients With Recurrent Invasive GliomasTerminatedNCT01269411Phase 1
• Vaccine Therapy and Sargramostim in Treating Patients With Malignant GliomaCompletedNCT01250470Phase 1
• Yoga Therapy in Treating Patients With Malignant Brain TumorsTerminatedNCT01234805Not applicable
• Bafetinib in Treating Patients With Recurrent High-Grade Glioma or Brain MetastasesCompletedNCT01234740Phase 1
• A Pilot Feasibility Study of Oral 5-Fluorocytosine and Genetically-Modified Neural Stem Cells Expressing E.Coli Cytosine Deaminase for Treatment of Recurrent High Grade GliomasCompletedNCT01172964Phase 1
• Fluorine F 18 Fluorodopa-Labeled PET Scan in Planning Surgery and Radiation Therapy in Treating Patients With Newly Diagnosed High- or Low-Grade Malignant GliomaCompletedNCT01165632Early Phase 1
• Bevacizumab and Temozolomide in Treating Older Patients With Newly-Diagnosed Glioblastoma Multiforme or GliosarcomaCompletedNCT01149850Phase 2
• Aminolevulinic Acid During Surgery in Treating Patients With Malignant Brain TumorsTerminatedNCT01148966Phase 1
• Gamma-Secretase Inhibitor RO4929097 and Cediranib Maleate in Treating Patients With Advanced Solid TumorsCompletedNCT01131234Phase 1
• Study of AR-67 in Adult Patients With Recurrence of Glioblastoma Multiforme (GBM) or GliosarcomaStatus unknownNCT01124539Phase 2
• Cilengitide and Sunitinib Malate in Treating Patients With Advanced Solid Tumors or Glioblastoma MultiformeTerminatedNCT01122888Phase 1
• RO4929097, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Malignant GliomaCompletedNCT01119599Phase 1
• Erlotinib Hydrochloride and Isotretinoin in Treating Patients With Recurrent Malignant GliomaTerminatedNCT01103375Phase 1
• Radiosurgery Plus Bevacizumab in GlioblastomaTerminatedNCT01086345Early Phase 1
• Phase I Study of Cellular Immunotherapy for Recurrent/Refractory Malignant Glioma Using Intratumoral Infusions of GRm13Z40-2, An Allogeneic CD8+ Cytolitic T-Cell Line Genetically Modified to Express the IL 13-Zetakine and HyTK and to be Resistant to Glucocorticoids, in Combination With Interleukin-2CompletedNCT01082926Phase 1
• Cediranib Maleate and Cilengitide in Treating Patients With Progressive or Recurrent GlioblastomaCompletedNCT00979862Phase 1
• Safety Study of XL184 (Cabozantinib) in Combination With Temozolomide and Radiation Therapy in the Initial Treatment of Adults With GlioblastomaCompletedNCT00960492Phase 1
• Hyperbaric Hyperoxygenation With Radiotherapy and Temozolomide in Adults With Newly Diagnosed GlioblastomaStatus unknownNCT00936052Phase 2

← Gliosarcoma overview